附件 10.18
2023年8月25日
David McErlane
亲爱的David,
恭喜您获得加入我们团队的机会！catalent聘用那些对全球数以百万计人群健康产生影响力的人。您的专业知识，结合catalent的专业知识和能力，以及与成千上万创新药品、生物科技和医疗公司的合作，将帮助我们研发、供应和提供数十亿剂增进生活质量产品。我们很自豪能聘用像您这样具有才华、动力和承诺的专业人士。我们迫不及待地期待您加入我们，一起努力为全球患者带来新药。我们相信您在catalent的职业生涯将充满机遇、新挑战和有意义的工作。附上了我们组织以及您个人职位、奖励和福利的重要信息。
您的聘用条件，须经catalent 董事会或其薪酬和领导委员会（CLC）批准，内容如下:
职位: 您的职位将是 生物制品集团总裁，位于马里兰州巴尔的摩，直接向总裁Alessandro Maselli汇报。您还将成为Catalent执行领导团队（ELT）的成员。
薪酬： 您的 每两周 底薪将是20,192美元（年化为 $525,000). Catalent 员工每隔一星期五支付一次薪水，延迟一周（比您完成的最新工作周少一周）。
表现： 绩效和基于表现的薪酬会被视为年度流程的一部分进行审查，此程序通常于财政年度最后一季开始，并在接下来的财政年度首季结束。假设您的开始控制项日期仍为2023年9月25日左右，您的第一次薪酬审查可能会在2024年7月1日开始的财政年度流程中发生。
奖励： Catalent很高兴提供一个全面、具竞争力的薪酬计划，以表扬表现优秀的员工。自您入职的第一天起，您将有资格参加我们的健康、生命、残障以及401(k)养老储蓄计划，以及所有其他通常提供给我们美国员工的计划和程序。您将在新员工培训课程中获得有关这些福利的更多信息。此外，你将收到或有资格参加以下项目：
| • | 您有资格参加Catalent的短期激励计划，我们称为管理激励计划（MIP）。您的年度激励目标将是 $420,000。您将有资格在我们2024财政年度（2023年7月1日至2024年6月30日）开始时获得MIP奖金 本协议书中的任何标点符号、启动列符号或基于任何形式的柢栏容器，在翻译时均应维持不变。 ，基于您的入职日期。年度奖金支付根据达成程度决定 |
第1页，共4页
| 特定公司和个人目标的达成并不保证。为了收到您的MIP支付，您必须在支付时仍在积极就业。 |
| • | 为了表彰您的领导地位，我们建议您获得一项长期奖励计划（LTIP）的年度补助，金额等同于 $925,000由于LTIP补助包含股权元件，您的补助需经过CLC的批准。初始补助日期将在您的开始日期后尽快进行。未来几年，LTIP补助将根据Catalent标准股权补助周期的第一季度进行。 LTIP的所有条款和条件，包括股权成分和相关奖励协议，将在您入职日期后不久提供给您，并受到您接受特定限制承诺等条件的限制。 |
| • | 入职时，您将获得 $300,000 现金，作为 报到奖金 奖金。此现金支付将在您入职日期起的24个月内，如您自愿离开公司或因原因被解雇，将全额追回且不考虑已支付的税款。 |
| • | 经CLC批准后，您将获得一个特别的限制股票单位（RSU）“偿还”和 “签约奖金” 赋予赋予日期值的赋予 $590,000这些RSU的股份将在您的赋予日期的头三个周年均等分期生效。此赋予将受到类似于年度LTIP奖励的条款和条件约束，唯独不符合“65条款”退休福利。 |
| • | 作为ELt的成员，您将有资格参加Catalent的递延薪酬计划，该计划可让您在符合资格的401(k)计划中超过IRS限额进行储蓄。有关此计划的功能详细资料和如何注册将在您入职后通过邮件寄送到您的家中。您还将有资格享有ELt成员通常可用的所有其他福利，包括： |
| • | 财务规划： 每个日历年度，作为ELt的成员，您可以透过使用高盛的财务规划部门AYCO或您选择的财务规划师进行财务规划。如果选择自选财务规划师，您每年的最高退款额为17,000美元，该金额将被视为应税收入并相应税收。入职后将提供更多有关财务规划的详细资料。 |
带薪休假： 加入catalent后，您将获得八（8）个带薪公司假期（元旦、MLK日、阵亡将士纪念日、独立日、劳动节、感恩节及次日、圣诞节）。此外：
| • | 您将有资格每年获得208小时(26天)的日历年度PTO，本协议书中的任何标点符号、启动列符号或基于任何形式的柢栏容器，在翻译时均应维持不变。 在您的第一年内，根据您被雇用的月数，将根据catalent现行公司PTO政策增加PTO福利。 PTO包括假期、病假和个人休假。未使用的PTO可以按照catalent的PTO政策中规定的方式进行结转。 |
开始控制项 日期: 您的首个工作日将是2023年9月25日，须具备满意的背景调查和药物筛选测试结果。
遣散费： 您将收到一份单独的解聘信协议，其中规定您有资格获得等于您年度基本薪水加上MIP目标奖金的解聘福利，须遵守信函协议的条款。
股权拥有: 作为生物制品集团总裁，您将受到catalent的执行股权拥有指引的限制。这些文件可向人力资源部获取。
第4页，共4页
要求项目： 符合我们所有catalent人员政策和我们行业的特殊考量，此优惠取决于满足药物筛查和背景调查，包括参考核查的满意完成。
| • | 由公司支付的 药物筛查必须在您开始控制项日期前的30个日历内完成，并取得可接受的结果。 在接受此优惠后，我们的供应商将透过email向您发送一份样品联系单，该联系单是您进行药物筛查所必需的，并提供如何完成药物筛查的信息。 若任何条款被法律禁止，又或因法院裁定为无效或无法强制执行，该条款视为经修改后广泛应用，以符合有效性及可强制性的最大范围，其无效性或无法强制性，不影响本协议其余条款的有效性，只要经修改后完整表达各方对于意图，相对的期望或义务并不遭受实质损害或减少，实际获得的利益和权利不受侵害。双方将本著善意协商精神，努力以有效约束替代被禁止，无效或无法强制执行之条款，恢复其原来的效力。此协议书或任何其他交易文件，双方均不得违反任何适用法律或法规的限制，支付或收取的款项( 包括应按照适用法律被视为“利息”项目之款项) 不得超过任何适用法律所允许的金额。 因此， 如果根据法律最终被判定去支付的任何义务，由任何买方支付的金额，或者由公司或其附属公司(如适用)支付或应支付的款项或买方根据本协议书收取的款项，被最终的司法裁判认定违反任何这些适用法律，该义务支付、支付或收取被视作买方、公司及其附属公司之间的相互失误。被视为已调整其最高金额或利率，作为不受该适用法律禁止之最大金额或利率，并具有追溯效力。该调整将通过减少或退还买方可选择的利息或根据交易文件支付的任何其他金额来实现。以下是更大的明确性，若依据任何交易文件或相关条款支付给买方的利息、费用、开支或其他任何金额，在适用法律内被视为“利息”或其他适用性词语，可能而被认为违反适用法律，则该金额必须按照所属时段进行比例分配。 若任何条款被法律禁止，又或因法院裁定为无效或无法强制执行，该条款视为经修改后广泛应用，以符合有效性及可强制性的最大范围，其无效性或无法强制性，不影响本协议其余条款的有效性，只要经修改后完整表达各方对于意图，相对的期望或义务并不遭受实质损害或减少，实际获得的利益和权利不受侵害。双方将本著善意协商精神，努力以有效约束替代被禁止，无效或无法强制执行之条款，恢复其原来的效力。此协议书或任何其他交易文件，双方均不得违反任何适用法律或法规的限制，支付或收取的款项( 包括应按照适用法律被视为“利息”项目之款项) 不得超过任何适用法律所允许的金额。 因此， 如果根据法律最终被判定去支付的任何义务，由任何买方支付的金额，或者由公司或其附属公司(如适用)支付或应支付的款项或买方根据本协议书收取的款项，被最终的司法裁判认定违反任何这些适用法律，该义务支付、支付或收取被视作买方、公司及其附属公司之间的相互失误。被视为已调整其最高金额或利率，作为不受该适用法律禁止之最大金额或利率，并具有追溯效力。该调整将通过减少或退还买方可选择的利息或根据交易文件支付的任何其他金额来实现。以下是更大的明确性，若依据任何交易文件或相关条款支付给买方的利息、费用、开支或其他任何金额，在适用法律内被视为“利息”或其他适用性词语，可能而被认为违反适用法律，则该金额必须按照所属时段进行比例分配。 亦会包含离您家庭地址最近的检测设施联系资讯。请务必携带该文件的列印本。 若任何条款被法律禁止，又或因法院裁定为无效或无法强制执行，该条款视为经修改后广泛应用，以符合有效性及可强制性的最大范围，其无效性或无法强制性，不影响本协议其余条款的有效性，只要经修改后完整表达各方对于意图，相对的期望或义务并不遭受实质损害或减少，实际获得的利益和权利不受侵害。双方将本著善意协商精神，努力以有效约束替代被禁止，无效或无法强制执行之条款，恢复其原来的效力。此协议书或任何其他交易文件，双方均不得违反任何适用法律或法规的限制，支付或收取的款项( 包括应按照适用法律被视为“利息”项目之款项) 不得超过任何适用法律所允许的金额。 因此， 如果根据法律最终被判定去支付的任何义务，由任何买方支付的金额，或者由公司或其附属公司(如适用)支付或应支付的款项或买方根据本协议书收取的款项，被最终的司法裁判认定违反任何这些适用法律，该义务支付、支付或收取被视作买方、公司及其附属公司之间的相互失误。被视为已调整其最高金额或利率，作为不受该适用法律禁止之最大金额或利率，并具有追溯效力。该调整将通过减少或退还买方可选择的利息或根据交易文件支付的任何其他金额来实现。以下是更大的明确性，若依据任何交易文件或相关条款支付给买方的利息、费用、开支或其他任何金额，在适用法律内被视为“利息”或其他适用性词语，可能而被认为违反适用法律，则该金额必须按照所属时段进行比例分配。 以及一份政府核发的身份证明文件，一同携至该设施以进行药物筛检。 |
| • | 在您入职前必须完成背景调查，包括参考检查，并获得满意的结果。您将收到一封来自我们供应商的订单，内含如何完成必要文件以启动所需的检查程序并提供授权。 若任何条款被法律禁止，又或因法院裁定为无效或无法强制执行，该条款视为经修改后广泛应用，以符合有效性及可强制性的最大范围，其无效性或无法强制性，不影响本协议其余条款的有效性，只要经修改后完整表达各方对于意图，相对的期望或义务并不遭受实质损害或减少，实际获得的利益和权利不受侵害。双方将本著善意协商精神，努力以有效约束替代被禁止，无效或无法强制执行之条款，恢复其原来的效力。此协议书或任何其他交易文件，双方均不得违反任何适用法律或法规的限制，支付或收取的款项( 包括应按照适用法律被视为“利息”项目之款项) 不得超过任何适用法律所允许的金额。 因此， 如果根据法律最终被判定去支付的任何义务，由任何买方支付的金额，或者由公司或其附属公司(如适用)支付或应支付的款项或买方根据本协议书收取的款项，被最终的司法裁判认定违反任何这些适用法律，该义务支付、支付或收取被视作买方、公司及其附属公司之间的相互失误。被视为已调整其最高金额或利率，作为不受该适用法律禁止之最大金额或利率，并具有追溯效力。该调整将通过减少或退还买方可选择的利息或根据交易文件支付的任何其他金额来实现。以下是更大的明确性，若依据任何交易文件或相关条款支付给买方的利息、费用、开支或其他任何金额，在适用法律内被视为“利息”或其他适用性词语，可能而被认为违反适用法律，则该金额必须按照所属时段进行比例分配。 在您入职的第一天，您将收到一份Catalent Pharma Solutions的文件并被要求签署保密协议。 |
| • | 1986年的《移民改革和控制法案》要求雇主验证所有新员工的就业合法性和身份。依据此法案，请务必在入职的第一天携带适当的识别文件。 |
| • | 您的第一天工作将收到并被要求签署Catalent Pharma Solutions的保密协议。 1-9 完成所有前置聘用条件后，将向您发送一份包括接受的工作许可证明文件清单。 聘用前 应急情况。 |
| • | Catalent不雇用员工，以谋取其前雇主的商业机密、知识产权或其他机密或专有信息。在这方面，Catalent期望您遵守对您前任雇主的法律义务，并且您不得在任何情况下利用您前任雇主的任何机密或专有信息以代表Catalent从事业务。 |
| • | 您接受此聘用提议的签名也代表您确认您不是涉及您在Catalent的职责的不竞争或不招揽协议的一方，或者您是此类协议的一方并将遵守您当前（和/或以往）雇主的法律义务。如果您认为自己无法根据任何合法且适用的限制在Catalent有效履行职责，您必须立即通知Catalent。此外，如果您的前雇主因您受雇于Catalent而采取任何法律行动，Catalent将无需支付或赔偿您的法律费用、代表费用或与该法律行动有关的损害。Catalent将根据当时情况采取适当的步骤。 |
期限： 与Catalent的雇佣关系没有明确的时间期限，可以由您或公司随时或无需通知或理由终止。不应有任何明示或暗示的雇佣合同。
道德： 作为一家建立在一系列核心价值观基础上的公司，您将收到catalent 的业务行为标准，并需要在就业开始时签署合规函，以及之后不时地进行签署。
第4页中的第3页
请透过扫描/邮件将签署/日期版的这份录取函副本寄至我的注意。
如果您有任何问题，请随时与我联络。
此致，顺祝商祺。
| /s/ Lisa Evoli |
| Lisa Evoli |
我接受以上的就业录取。
| /s/ 大卫·麦克尔恩 | 2023年8月27日 | |||
| 大卫·麦克尔兰 | 日期 |
第4页，共4页
August 25, 2023
David McErlane
Re: Severance Benefits
Dear David,
This letter will memorialize the severance payments and benefits to which you will be entitled if your employment with Catalent Pharma Solutions, LLC (the “Company”) ceases under specified circumstances. This letter is effective as of September 25, 2023, the date of your commencement of employment.
Specifically, if you separate from employment with the Company because (i) you are involuntarily terminated by the Company for a reason other than Cause (as defined below), (ii) you die or become Disabled (as defined below), or (iii) you resign from your position with the Company for Good Reason (as defined and in accordance with the terms and conditions set forth below), you will receive the following severance payments and benefits on account of such separation (subject to applicable withholdings and deductions[, as well as the terms and conditions of payment provided below]):
| (a) | A severance payment equal to the sum of your annual base salary and target annual cash bonus, payable in equal installments over the one (1) year period following the date of your termination of employment (the “Severance Period”), consistent with the normal payroll practices of the Company; and |
| (b) | If you elect COBRA continuation coverage, you will continue to receive the group health benefits coverage in effect on your termination date (or generally comparable coverage) for yourself and, where applicable, your spouse and eligible dependents (to the extent they were receiving such coverage as of the termination date), at the same premium rates as may be charged from time to time for employees of the Company generally, which coverage shall be provided until the earliest to occur of (x) the expiration of the Severance Period, (y) the date you are or become eligible for coverage under group health plan(s) of any other employer, and (z) the date you are no longer eligible for COBRA continuation coverage. Such continued coverage shall run concurrently with any available COBRA coverage. Notwithstanding anything to the contrary in the foregoing, if the Company determines, in its reasonable judgment, that providing group health benefits in accordance with the preceding provisions of this paragraph would result in a violation of applicable law, the imposition of any penalty under applicable law, or adverse tax consequences for any participant covered by the Company’s group health benefits plans, the Company may terminate such coverage (or reimbursement) and instead pay you taxable cash payments at the same time and in the same amounts as you would be required to pay as premiums to obtain such coverage. |
These severance payments and benefits are conditioned on you signing and not revoking the Company’s standard form of release of claims used with Company executives generally (the “Release”) within sixty days of your termination of employment. The first such payment shall begin on the first payroll date following the date you have executed and returned the Release and such Release is no longer subject to revocation; provided further that, if required to avoid additional taxes or penalties under Section 409A of the Internal Revenue Code (the “Code”) and the rules and regulations thereunder (collectively, “Section 409A”), if the period to return the Release begins in one taxable year and ends in a subsequent taxable year, payment will not commence until the subsequent taxable year, and in all cases the first such payment shall include any amount that would otherwise have been paid between the date of your termination of employment and the first such payment
In addition, your entitlement to the severance payments and benefits are conditioned on your compliance with (a) the non-competition and non- solicitation provisions in each equity grant agreement you execute or have executed in connection with your
Page 1 of 3
employment or your compensation as a Catalent employee and (b) the confidentiality obligations imposed on you by our Standards of Business Conduct and each equity grant agreement you execute or have executed in connection with your employment or your compensation as a Catalent employee. You acknowledge that neither your employment nor any termination of employment has created or will create any entitlement to these severance payments and benefits other than as set forth in this letter.
For purposes of this letter, the following terms shall have the following meanings:
| • | “Cause” means: (i) your willful failure to perform your duties, which failure is not cured within fifteen (15) days following written notice from the Company; (ii) your conviction or confessing to or becoming subject to proceedings that provide a reasonable basis for the Company to believe that you have engaged in a (x) felony, (y) crime involving dishonesty, or (z) crime (A) involving moral turpitude and (B) demonstrably injurious to the Company or its subsidiaries or affiliates; (iii) your willful malfeasance or misconduct that is demonstrably injurious to the Company or its subsidiaries or affiliates; or (iv) material breach by you of any non-competition, non-solicitation or confidentiality obligation in any agreement you execute or have executed in connection with your employment or your compensation as a Catalent employee. For purposes of this definition, no act or failure to act will be deemed “willful” unless effected by you not in good faith. |
| • | “Change in Control” has the meaning set forth in the Catalent, Inc. 2018 Omnibus Incentive Plan, as may be amended or modified from time to time (or any successor plan) (provided, however, that, if required to avoid additional taxes under Section 409A, in order to be a Change in Control, the transaction must also be a “change in ownership or effective control” or a “change in the ownership of a substantial portion of the assets” under Section 409A). |
| • | “Disabled” means you become permanently disabled and as a consequence become entitled to receive benefits under the Company’s then-current long-term disability insurance program (provided, however, that, if required to avoid additional taxes under Section 409A, you must also be considered “disabled” under Section 409A). |
| • | “Good Reason” means, without your consent: (i) a substantial diminution in your position or duties, adverse change in reporting lines, up and down, or assignment of duties materially inconsistent with your position; (ii) a material reduction in your base salary; (iii) failure of the Company to pay you compensation or benefits when due; (iv) the Company’s failure to provide you with an annual bonus opportunity that is at the same level as established in your offer letter dated August 25, 2023 or any subsequent increase in that level made available to you; or (v) you are required to move your principal business location more than fifty (50) miles; in each case, provided that (A) you have given written notice to the Company (which such notice shall describe in reasonable detail the conduct you believe constitutes Good Reason) within sixty (60) days following the occurrence of the event(s) that constitute Good Reason, (B) the Company shall have thirty (30) days to cure such events, and (C) to the extent the Company fails to cure such event within the thirty (30) day cure period, you terminate employment within thirty (30) days after the end of such cure period. |
Please note that, with respect to your outstanding equity rights at the time of your termination of employment, your individual grant agreement(s) and the related equity documents set forth the consequences of your termination of employment on such equity rights.
The Company makes no representation regarding the tax implications of the compensation and benefits paid to you hereunder, including, without limitation, the implications under Section 409A. It is intended that this letter and the payments and benefits hereunder will either comply with or be exempt from Section 409A to the extent applicable, and the letter shall be interpreted on a basis consistent with such intent. Notwithstanding anything to the contrary in the foregoing, you are solely responsible for, and neither the Company nor any of its subsidiaries or affiliates shall have any liability for, any additional tax, interest, or penalty that may be imposed on you under Section 409A. Notwithstanding anything in this letter to the contrary, in the event that you are deemed to be a “specified employee” within the meaning of Section 409A(a)(2)(8)(i), no payment hereunder that constitutes “deferred compensation” subject to Section 409A shall, to the extent required to avoid additional taxes under Section 409A, be made to you prior to the date that is six (6) months after the date of your “separation from service” (as defined in Section 409A) or, if earlier, your death. Following any applicable six (6) month delay, all such delayed payments will be paid in a single lump sum on the earliest permissible payment date. For purposes hereof, (A) with respect to payments of any amount that is considered to be “deferred compensation” subject to Section 409A, references to “termination of employment” (and substantially similar phrases) shall refer to a “separation from service” within the meaning of Section 409A and (8) your right to receive any installment payment will be treated as a right to receive a series of separate and distinct payments.
Notwithstanding anything herein to the contrary, if the payments and benefits to be provided to you by the Company (or its subsidiaries or affiliates), whether or not provided hereunder, either alone or together with any other payment or benefit you have a right to receive, would constitute a “parachute payment” under Section 280G of the Code and but for this paragraph would be subject to the excise tax (imposed by Section 4999 of the Code (the “Excise Tax”), then any such payment or benefit to be provided by the Company (or its subsidiaries or affiliates) shall equal either (i) the largest portion of the payments and benefits that would result in no portion of the payments and benefits being subject to the Excise Tax (the “Reduced Amount”) or
Page 2 of 3
(ii) the full amount of all such payments and benefits, whichever amount, after taking into account all applicable federal, state, and local employment taxes, income taxes and the Excise Tax (all computed at the highest applicable marginal rate), results in your receipt, on an after-tax basis, of the greater amount of the payments and benefits, notwithstanding that all or some portion of the payments and benefits may be subject to the Excise Tax. If a reduction in payments and benefits constituting “parachute payments” is necessary so that the payments and benefits equal the Reduced Amount, the reduction of such payments and/or benefits, if applicable, shall be made as follows, in each case with payments and benefits with a higher “parachute payment” value for purposes of section 280G reduced before payments with a lower value: (i) reduction of payments hereunder, (ii) reduction of vesting acceleration of equity awards; and (iii) reduction of other cash payments. No such reduction shall be made if and to the extent it would result in additional taxes under Section 409A. Any such determination shall be made by a nationally accredited accounting firm chosen by the Company (with the fees and expenses of such firm to be borne by the Company). The determination of the accounting firm shall be binding upon the Company and you.
Your agreement to the terms of this letter supersedes any other oral or written agreement or understanding you may have with the Company or any of its subsidiaries or affiliates (including any predecessor entity) regarding your eligibility for severance payments and benefits.
This letter will be subject to the internal substantive laws, and not the choice of law rules, of the State of Maryland.
Please sign below your agreement to the terms of this letter. This letter may be signed in counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. Notice under this agreement may be sent to you at any then-current personal physical or email address of yours on file with the Company and notice to us to attention of the CEO at the Company’s principal address.
If you have any question regarding these severance payments and benefits, please feel free to contact me or Steven Fasman at .
Sincerely yours,
| /s/ Lisa Evoli |
| Lisa Evoli |
| Senior VP & Chief Human Resources Officer |
By signing below, I hereby agree to the terms and conditions of this letter.
| /s/ David McErlane | 27 Aug 2023 | |||
| David McErlane | Date |
Page 3 of 3